Literature DB >> 22683685

Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition.

David L Burns1, Brian M Gill.   

Abstract

Patients with intestinal failure and short bowel syndrome usually require chronic parenteral nutrition (PN). PN is associated with risks, including infections, vascular thrombosis, and liver disease. PN-associated liver disease (PNALD) can progress from steatosis to chronic hepatitis and ultimately to cirrhosis. The etiology of PNALD is not completely understood. Therapies for PNALD include carbohydrate or lipid calorie reduction, antibiotics, or the use of ursodeoxycholic acid. When these efforts fail, therapeutic options are limited and liver transplantation may be required. The transition from a soybean- to a fish oil-based lipid formulation, such as the ω-3 parenteral lipid formulation (Omegaven), has shown a dramatic reversal of PNALD within the pediatric population. This is the first report of a PN-dependent adult in the United States complicated by PNALD and hepatic failure who had improvement of liver disease with an ω-3 fish oil-based parenteral formulation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22683685     DOI: 10.1177/0148607112450301

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  16 in total

Review 1.  Mechanisms of Parenteral Nutrition-Associated Liver and Gut Injury.

Authors:  Himani Madnawat; Adam L Welu; Ester J Gilbert; Derian B Taylor; Sonali Jain; Chandrashekhara Manithody; Keith Blomenkamp; Ajay K Jain
Journal:  Nutr Clin Pract       Date:  2019-12-23       Impact factor: 3.080

2.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

Review 3.  The concept of gut rehabilitation and the future of visceral transplantation.

Authors:  Kareem Abu-Elmagd
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-01-20       Impact factor: 46.802

Review 4.  Fish oil-based lipid emulsion: current updates on a promising novel therapy for the management of parenteral nutrition-associated liver disease.

Authors:  Shishira Bharadwaj; Tushar Gohel; Omer J Deen; Robert DeChicco; Abdullah Shatnawei
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-04-08

5.  The relationship between the parenteral dose of fish oil supplementation and the variation of liver function tests in hospitalized adult patients.

Authors:  Maria B Badia-Tahull; Elisabet Leiva-Badosa; Ramon Jodar-Masanes; Josep Maria Ramon-Torrell; Josep Llop-Talaveron
Journal:  Nutr J       Date:  2015-07-02       Impact factor: 3.271

6.  Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parenteral nutrition-associated liver disease.

Authors:  Alfonso Pastor-Clerigues; Ezequiel Marti-Bonmati; Javier Milara; Patricia Almudever; Julio Cortijo
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

7.  Reversal of intestinal failure-associated liver disease (IFALD): emphasis on its multifactorial nature.

Authors:  Christian Hvas; Kamelia Kodjabashia; Emma Nixon; Stephen Hayes; Kirstine Farrer; Arun Abraham; Simon Lal
Journal:  Frontline Gastroenterol       Date:  2015-04-09

Review 8.  Controversies in the Mechanism of Total Parenteral Nutrition Induced Pathology.

Authors:  Jain Ajay Kumar; Jeffery H Teckman
Journal:  Children (Basel)       Date:  2015-07-31

Review 9.  Choice of Allograft in Patients Requiring Intestinal Transplantation: A Critical Review.

Authors:  Genevieve Huard; Thomas Schiano; Jang Moon; Kishore Iyer
Journal:  Can J Gastroenterol Hepatol       Date:  2017-05-03

Review 10.  The use of fish oil lipid emulsion in the treatment of intestinal failure associated liver disease (IFALD).

Authors:  Melissa I Chang; Mark Puder; Kathleen M Gura
Journal:  Nutrients       Date:  2012-11-27       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.